LPX Lipoxen

 

TIDMLPX 
 
 
Lipoxen PLC 
26 May 2010 
 
? 
+---------------------------------+---------------------------------+ 
| FOR IMMEDIATE RELEASE           |                     26 May 2010 | 
| RNS Reach                       |                                 | 
+---------------------------------+---------------------------------+ 
 
 
 
                                  Lipoxen plc 
                          ('Lipoxen' or 'the Company') 
                  Expansion of DNA Vaccine Patent Allowed in US 
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, announces today that an expansion of its DNA Vaccine Patent ("Patent") 
has been allowed in the US for its ImuXen  liposomal gene technology. 
The ImuXen  technology allows the liposomal entrapment of vaccine materials, 
resulting in enhanced immune responses which potentially could lead to single 
dose immunity being achieved while reducing the side effects associated with 
traditional vaccines. The new Patent protects the use of a range of additional 
cationic lipids that can form the building molecules of Lipoxen's ImuXen 
liposomes. 
This Patent expansion strengthens and broadens Lipoxen's existing ImuXen 
patents which protect the co-delivery DNA and antigen and delivery of antigen 
alone. 
Commenting on these results, Scott Maguire, CEO said: "This Patent extension is 
important as it further protects the patent position of our gene vaccine 
technology.  Such added protection will provide value to commercial partners 
seeking long term exclusivity in the vaccine market." 
For further information, please contact: 
Enquiries 
+------------------------------------------+--------------------+ 
| Lipoxen plc                              |     +44 (0)20 7389 | 
|                                          |               5015 | 
+------------------------------------------+--------------------+ 
| M. Scott Maguire, Chief Executive        |                    | 
| Officer                                  |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Singer Capital Markets (nominated        |     +44 (0)20 3205 | 
| adviser)                                 |               7500 | 
+------------------------------------------+--------------------+ 
| Jeff Keating / Claes Spång               |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Buchanan Communications                  |     +44 (0)20 7466 | 
|                                          |               5000 | 
+------------------------------------------+--------------------+ 
| Lisa Baderoon, Catherine Breen           |                    | 
+------------------------------------------+--------------------+ 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines.  Lipoxen has three proprietary patented 
technology platforms: 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
Lipoxen has multiple drug and vaccine programmes in development.  Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and an exclusive license deal with 
Baxter Healthcare for Factor VIII. 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities.  Lipoxen currently has commercial agreements with some 
of the world's leading biotechnology and pharmaceutical companies including 
Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and 
Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and 
management led the GBP2.9 million fundraising that the Company announced in May 
2009. This fundraising was followed up by a GBP1.2 million placing in April 
2010. 
 
Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock 
Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAQELFLBEFLBBL 
 

Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024